

1 A bill to be entitled
2 An act relating to the Department of Health; amending
3 chapter 2023-43, Laws of Florida; revising the repeal
4 date of the definition of the term "messenger
5 ribonucleic acid vaccine"; providing for contingent
6 retroactive operation; reenacting ss. 381.00316(2)(g)
7 and 381.00319(1)(e), F.S., relating to the prohibition
8 on discrimination by governmental and business
9 entities based on health care choices and the
10 prohibition on mask mandates and vaccination and
11 testing mandates for educational institutions,
12 respectively, for purposes of preserving the
13 definition of the term "messenger ribonucleic acid
14 vaccine," notwithstanding its scheduled repeal;
15 amending s. 381.986, F.S.; defining terms for purposes
16 of background screening requirements for persons
17 affiliated with medical marijuana treatment centers;
18 requiring medical marijuana treatment centers to
19 notify the Department of Health through e-mail within
20 a specified timeframe after an actual or attempted
21 theft, diversion, or loss of marijuana; requiring
22 medical marijuana treatment centers to report
23 attempted thefts, in addition to actual thefts, to law
24 enforcement within a specified timeframe; amending s.
25 381.988, F.S.; defining terms for purposes of

26 background screening requirements for persons
27 affiliated with medical marijuana testing
28 laboratories; amending s. 456.0145, F.S.; revising
29 eligibility criteria for licensure by endorsement
30 under the MOBILE Act; amending s. 456.44, F.S.;
31 revising the definition of the term "board-certified
32 pain management physician" to replace the term
33 "American Association of Physician Specialists" with
34 "American Board of Physician Specialties"; making a
35 technical change; amending s. 458.313, F.S.; revising
36 the qualifications required for a person seeking
37 licensure by endorsement as an allopathic physician;
38 amending s. 458.3145, F.S.; revising the list of
39 institutions at which the department is authorized to
40 issue a medical faculty certificate to an individual
41 who has been offered and has accepted a full-time
42 faculty appointment; amending ss. 458.315 and
43 459.0076, F.S.; revising criteria authorizing
44 physician assistants to be issued temporary
45 certificates for practice in areas of critical need;
46 amending ss. 458.3265, 458.3475, 459.0137, and
47 459.023, F.S.; revising definitions to replace the
48 term "American Association of Physician Specialists"
49 with "American Board of Physician Specialties";
50 amending s. 486.112, F.S.; defining the term "party

51 state"; authorizing a remote state to issue subpoenas
52 to individuals to testify or for the production of
53 evidence from a party located in a party state;
54 providing that such subpoenas are enforceable in the
55 party state; requiring that investigative information
56 pertaining to certain licensees in a certain system be
57 available only to other party states; revising
58 construction and severability of the compact to
59 conform to changes made by the act; providing
60 effective dates.

61
62 Be It Enacted by the Legislature of the State of Florida:

63
64 Section 1. Effective upon becoming a law, or, if this act
65 fails to become a law until after June 1, 2025, operating
66 retroactively to June 1, 2025, section 9 of chapter 2023-43,
67 Laws of Florida, is amended to read:

68 Section 9. Sections 381.00316(2)(g) and 381.00319(1)(e),
69 Florida Statutes, as created by this act, are repealed June 1,
70 2027 2025.

71 Section 2. Effective upon becoming a law, or, if this act
72 fails to become a law until after June 1, 2025, operating
73 retroactively to June 1, 2025, paragraph (g) of subsection (2)
74 of section 381.00316, Florida Statutes, is reenacted to read:

75 381.00316 Discrimination by governmental and business

76 entities based on health care choices; prohibition.—

77 (2) As used in this section, the term:

78 (g) "Messenger ribonucleic acid vaccine" means any vaccine
79 that uses laboratory-produced messenger ribonucleic acid to
80 trigger the human body's immune system to generate an immune
81 response.

82 Section 3. Effective upon becoming a law, or, if this act
83 fails to become a law until after June 1, 2025, operating
84 retroactively to June 1, 2025, paragraph (e) of subsection (1)
85 of section 381.00319, Florida Statutes, is reenacted to read:

86 381.00319 Prohibition on mask mandates and vaccination and
87 testing mandates for educational institutions.—

88 (1) For purposes of this section, the term:

89 (e) "Messenger ribonucleic acid vaccine" has the same
90 meaning as in s. 381.00316.

91 Section 4. Paragraphs (b), (e), and (f) of subsection (8)
92 of section 381.986, Florida Statutes, are amended to read:

93 381.986 Medical use of marijuana.—

94 (8) MEDICAL MARIJUANA TREATMENT CENTERS.—

95 (b) An applicant for licensure as a medical marijuana
96 treatment center must ~~shall~~ apply to the department on a form
97 prescribed by the department and adopted in rule. The department
98 shall adopt rules pursuant to ss. 120.536(1) and 120.54
99 establishing a procedure for the issuance and biennial renewal
100 of licenses, including initial application and biennial renewal

101 fees sufficient to cover the costs of implementing and
102 administering this section, and establishing supplemental
103 licensure fees for payment beginning May 1, 2018, sufficient to
104 cover the costs of administering ss. 381.989 and 1004.4351. The
105 department shall identify applicants with strong diversity plans
106 reflecting this state's commitment to diversity and implement
107 training programs and other educational programs to enable
108 minority persons and minority business enterprises, as defined
109 in s. 288.703, and veteran business enterprises, as defined in
110 s. 295.187, to compete for medical marijuana treatment center
111 licensure and contracts. Subject to the requirements in
112 subparagraphs (a)2.-4., the department shall issue a license to
113 an applicant if the applicant meets the requirements of this
114 section and pays the initial application fee. The department
115 shall renew the licensure of a medical marijuana treatment
116 center biennially if the licensee meets the requirements of this
117 section and pays the biennial renewal fee. However, the
118 department may not renew the license of a medical marijuana
119 treatment center that has not begun to cultivate, process, and
120 dispense marijuana by the date that the medical marijuana
121 treatment center is required to renew its license. An individual
122 may not be an applicant, owner, officer, board member, or
123 manager on more than one application for licensure as a medical
124 marijuana treatment center. An individual or entity may not be
125 awarded more than one license as a medical marijuana treatment

center. An applicant for licensure as a medical marijuana treatment center must demonstrate:

1. That, for the 5 consecutive years before submitting the application, the applicant has been registered to do business in this ~~the~~ state.

2. Possession of a valid certificate of registration issued by the Department of Agriculture and Consumer Services pursuant to s. 581.131.

3. The technical and technological ability to cultivate and produce marijuana, including, but not limited to, low-THC cannabis.

4. The ability to secure the premises, resources, and personnel necessary to operate as a medical marijuana treatment center.

5. The ability to maintain accountability of all raw materials, finished products, and any byproducts to prevent diversion or unlawful access to or possession of these substances.

6. An infrastructure reasonably located to dispense marijuana to registered qualified patients statewide or regionally as determined by the department.

7. The financial ability to maintain operations for the duration of the 2-year approval cycle, including the provision of certified financial statements to the department.

a. Upon approval, the applicant must post a \$5 million

151 performance bond issued by an authorized surety insurance
152 company rated in one of the three highest rating categories by a
153 nationally recognized rating service. However, a medical
154 marijuana treatment center serving at least 1,000 qualified
155 patients is only required to maintain a \$2 million performance
156 bond.

157 b. In lieu of the performance bond required under sub-
158 subparagraph a., the applicant may provide an irrevocable letter
159 of credit payable to the department or provide cash to the
160 department. If provided with cash under this sub-subparagraph,
161 the department must ~~shall~~ deposit the cash in the Grants and
162 Donations Trust Fund within the Department of Health, subject to
163 the same conditions as the bond regarding requirements for the
164 applicant to forfeit ownership of the funds. If the funds
165 deposited under this sub-subparagraph generate interest, the
166 amount of that interest must ~~shall~~ be used by the department for
167 the administration of this section.

168 8. That all owners, ~~officers, board members,~~ and managers
169 have passed a background screening pursuant to subsection (9).
170 As used in this subparagraph, the term:

171 a. "Manager" means any person with the authority to
172 exercise or contribute to the operational control, direction, or
173 management of an applicant or a medical marijuana treatment
174 center or who has authority to supervise any employee of an
175 applicant or a medical marijuana treatment center. The term

176 includes an individual with the power or authority to direct or
177 influence the direction or operation of an applicant or a
178 medical marijuana treatment center through board membership, an
179 agreement, or a contract.

180 b. "Owner" means any person who owns or controls a 5
181 percent or greater share of interests of the applicant or a
182 medical marijuana treatment center which include beneficial or
183 voting rights to interests. In the event that one person owns a
184 beneficial right to interests and another person holds the
185 voting rights with respect to such interests, then in such case,
186 both are considered the owner of such interests.

187 9. The employment of a medical director to supervise the
188 activities of the medical marijuana treatment center.

189 10. A diversity plan that promotes and ensures the
190 involvement of minority persons and minority business
191 enterprises, as defined in s. 288.703, or veteran business
192 enterprises, as defined in s. 295.187, in ownership, management,
193 and employment. An applicant for licensure renewal must show the
194 effectiveness of the diversity plan by including the following
195 with his or her application for renewal:

196 a. Representation of minority persons and veterans in the
197 medical marijuana treatment center's workforce;

198 b. Efforts to recruit minority persons and veterans for
199 employment; and

200 c. A record of contracts for services with minority

business enterprises and veteran business enterprises.

(e) A licensed medical marijuana treatment center shall cultivate, process, transport, and dispense marijuana for medical use. A licensed medical marijuana treatment center may not contract for services directly related to the cultivation, processing, and dispensing of marijuana or marijuana delivery devices, except that a medical marijuana treatment center licensed pursuant to subparagraph (a)1. may contract with a single entity for the cultivation, processing, transporting, and dispensing of marijuana and marijuana delivery devices. A licensed medical marijuana treatment center shall ~~must~~, at all times, maintain compliance with the criteria demonstrated and representations made in the initial application and the criteria established in this subsection. Upon request, the department may grant a medical marijuana treatment center a variance from the representations made in the initial application. Consideration of such a request must ~~shall~~ be based upon the individual facts and circumstances surrounding the request. A variance may not be granted unless the requesting medical marijuana treatment center can demonstrate to the department that it has a proposed alternative to the specific representation made in its application which fulfills the same or a similar purpose as the specific representation in a way that the department can reasonably determine will not be a lower standard than the specific representation in the application. A variance may not

226 be granted from the requirements in subparagraph 2. and
227 subparagraphs (b)1. and 2.

228 1. A licensed medical marijuana treatment center may
229 transfer ownership to an individual or entity who meets the
230 requirements of this section. A publicly traded corporation or
231 publicly traded company that meets the requirements of this
232 section is not precluded from ownership of a medical marijuana
233 treatment center. To accommodate a change in ownership:

234 a. The licensed medical marijuana treatment center shall
235 notify the department in writing at least 60 days before the
236 anticipated date of the change of ownership.

237 b. The individual or entity applying for initial licensure
238 due to a change of ownership must submit an application that
239 must be received by the department at least 60 days before the
240 date of change of ownership.

241 c. Upon receipt of an application for a license, the
242 department shall examine the application and, within 30 days
243 after receipt, notify the applicant in writing of any apparent
244 errors or omissions and request any additional information
245 required.

246 d. Requested information omitted from an application for
247 licensure must be filed with the department within 21 days after
248 the department's request for omitted information or the
249 application will ~~shall~~ be deemed incomplete and ~~shall be~~
250 withdrawn from further consideration and the fees ~~shall be~~

251 forfeited.

252 e. Within 30 days after the receipt of a complete
253 application, the department shall approve or deny the
254 application.

255 2. A medical marijuana treatment center, and any
256 individual or entity who directly or indirectly owns, controls,
257 or holds with power to vote 5 percent or more of the voting
258 shares of a medical marijuana treatment center, may not acquire
259 direct or indirect ownership or control of any voting shares or
260 other form of ownership of any other medical marijuana treatment
261 center.

262 3. A medical marijuana treatment center may not enter into
263 any form of profit-sharing arrangement with the property owner
264 or lessor of any of its facilities where cultivation,
265 processing, storing, or dispensing of marijuana and marijuana
266 delivery devices occurs.

267 4. All employees of a medical marijuana treatment center
268 must be 21 years of age or older and have passed a background
269 screening pursuant to subsection (9). As used in this
270 subparagraph, the term "employee" means any person employed by a
271 medical marijuana treatment center licensee in any capacity,
272 including those whose duties involve any aspect of the
273 cultivation, processing, transportation, or dispensing of
274 marijuana. This requirement applies to all employees, regardless
275 of the compensation received.

276 5. Each medical marijuana treatment center must adopt and
277 enforce policies and procedures to ensure employees and
278 volunteers receive training on the legal requirements to
279 dispense marijuana to qualified patients.

280 6. When growing marijuana, a medical marijuana treatment
281 center:

282 a. May use pesticides determined by the department, after
283 consultation with the Department of Agriculture and Consumer
284 Services, to be safely applied to plants intended for human
285 consumption, but may not use pesticides designated as
286 restricted-use pesticides pursuant to s. 487.042.

287 b. Must grow marijuana within an enclosed structure and in
288 a room separate from any other plant.

289 c. Must inspect seeds and growing plants for plant pests
290 that endanger or threaten the horticultural and agricultural
291 interests of the state in accordance with chapter 581 and any
292 rules adopted thereunder.

293 d. Must perform fumigation or treatment of plants, or
294 remove and destroy infested or infected plants, in accordance
295 with chapter 581 and any rules adopted thereunder.

296 7. Each medical marijuana treatment center must produce
297 and make available for purchase at least one low-THC cannabis
298 product.

299 8. A medical marijuana treatment center that produces
300 edibles must hold a permit to operate as a food establishment

pursuant to chapter 500, the Florida Food Safety Act, and must comply with all the requirements for food establishments pursuant to chapter 500 and any rules adopted thereunder. Edibles may not contain more than 200 milligrams of tetrahydrocannabinol, and a single serving portion of an edible may not exceed 10 milligrams of tetrahydrocannabinol. Edibles may not have a potency variance ~~of no~~ greater than 15 percent. Marijuana products, including edibles, may not be attractive to children; be manufactured in the shape of humans, cartoons, or animals; be manufactured in a form that bears any reasonable resemblance to products available for consumption as commercially available candy; or contain any color additives. To discourage consumption of edibles by children, the department shall determine by rule any shapes, forms, and ingredients allowed and prohibited for edibles. Medical marijuana treatment centers may not begin processing or dispensing edibles until after the effective date of the rule. The department shall also adopt sanitation rules providing the standards and requirements for the storage, display, or dispensing of edibles.

9. Within 12 months after licensure, a medical marijuana treatment center must demonstrate to the department that all of its processing facilities have passed a Food Safety Good Manufacturing Practices, such as Global Food Safety Initiative or equivalent, inspection by a nationally accredited certifying body. A medical marijuana treatment center must immediately stop

326 processing at any facility which fails to pass this inspection
327 until it demonstrates to the department that such facility has
328 met this requirement.

329 10. A medical marijuana treatment center that produces
330 prerolled marijuana cigarettes may not use wrapping paper made
331 with tobacco or hemp.

332 11. When processing marijuana, a medical marijuana
333 treatment center must:

334 a. Process the marijuana within an enclosed structure and
335 in a room separate from other plants or products.

336 b. Comply with department rules when processing marijuana
337 with hydrocarbon solvents or other solvents or gases exhibiting
338 potential toxicity to humans. The department shall determine by
339 rule the requirements for medical marijuana treatment centers to
340 use such solvents or gases exhibiting potential toxicity to
341 humans.

342 c. Comply with federal and state laws and regulations and
343 department rules for solid and liquid wastes. The department
344 shall determine by rule procedures for the storage, handling,
345 transportation, management, and disposal of solid and liquid
346 waste generated during marijuana production and processing. The
347 Department of Environmental Protection shall assist the
348 department in developing such rules.

349 d. Test the processed marijuana using a medical marijuana
350 testing laboratory before it is dispensed. Results must be

verified and signed by two medical marijuana treatment center employees. Before dispensing, the medical marijuana treatment center must determine that the test results indicate that low-THC cannabis meets the definition of low-THC cannabis, the concentration of tetrahydrocannabinol meets the potency requirements of this section, the labeling of the concentration of tetrahydrocannabinol and cannabidiol is accurate, and all marijuana is safe for human consumption and free from contaminants that are unsafe for human consumption. The department shall determine by rule which contaminants must be tested for and the maximum levels of each contaminant which are safe for human consumption. The Department of Agriculture and Consumer Services shall assist the department in developing the testing requirements for contaminants that are unsafe for human consumption in edibles. The department shall also determine by rule the procedures for the treatment of marijuana that fails to meet the testing requirements of this section, s. 381.988, or department rule. The department may select samples of marijuana from a medical marijuana treatment center facility which shall be tested by the department to determine whether the marijuana meets the potency requirements of this section, is safe for human consumption, and is accurately labeled with the tetrahydrocannabinol and cannabidiol concentration or to verify the result of marijuana testing conducted by a marijuana testing laboratory. The department may also select samples of marijuana

376 delivery devices from a medical marijuana treatment center to
377 determine whether the marijuana delivery device is safe for use
378 by qualified patients. A medical marijuana treatment center may
379 not require payment from the department for the sample. A
380 medical marijuana treatment center must recall marijuana,
381 including all marijuana and marijuana products made from the
382 same batch of marijuana, that fails to meet the potency
383 requirements of this section, that is unsafe for human
384 consumption, or for which the labeling of the
385 tetrahydrocannabinol and cannabidiol concentration is
386 inaccurate. The department shall adopt rules to establish
387 marijuana potency variations of no greater than 15 percent using
388 negotiated rulemaking pursuant to s. 120.54(2)(d) which accounts
389 for, but is not limited to, time lapses between testing, testing
390 methods, testing instruments, and types of marijuana sampled for
391 testing. The department may not issue any recalls for product
392 potency as it relates to product labeling before issuing a rule
393 relating to potency variation standards. A medical marijuana
394 treatment center must also recall all marijuana delivery devices
395 determined to be unsafe for use by qualified patients. The
396 medical marijuana treatment center must retain records of all
397 testing and samples of each homogeneous batch of marijuana for
398 at least 9 months. The medical marijuana treatment center must
399 contract with a marijuana testing laboratory to perform audits
400 on the medical marijuana treatment center's standard operating

procedures, testing records, and samples and provide the results to the department to confirm that the marijuana or low-THC cannabis meets the requirements of this section and that the marijuana or low-THC cannabis is safe for human consumption. A medical marijuana treatment center shall reserve two processed samples from each batch and retain such samples for at least 9 months for the purpose of such audits. A medical marijuana treatment center may use a laboratory that has not been certified by the department under s. 381.988 until such time as at least one laboratory holds the required certification, but in no event later than July 1, 2018.

e. Package the marijuana in compliance with the United States Poison Prevention Packaging Act of 1970, 15 U.S.C. ss. 1471 et seq.

f. Package the marijuana in a receptacle that has a firmly affixed and legible label stating the following information:

(I) The marijuana or low-THC cannabis meets the requirements of sub-subparagraph d.

(II) The name of the medical marijuana treatment center from which the marijuana originates.

(III) The batch number and harvest number from which the marijuana originates and the date dispensed.

(IV) The name of the physician who issued the physician certification.

(V) The name of the patient.

(VI) The product name, if applicable, and dosage form, including concentration of tetrahydrocannabinol and cannabidiol. The product name may not contain wording commonly associated with products that are attractive to children or which promote the recreational use of marijuana.

(VII) The recommended dose.

(VIII) A warning that it is illegal to transfer medical marijuana to another person.

(IX) A marijuana universal symbol developed by the department.

12. The medical marijuana treatment center shall include in each package a patient package insert with information on the specific product dispensed related to:

- a. Clinical pharmacology.
- b. Indications and use.
- c. Dosage and administration.
- d. Dosage forms and strengths.
- e. Contraindications.
- f. Warnings and precautions.
- g. Adverse reactions.

13. In addition to the packaging and labeling requirements specified in subparagraphs 11. and 12., marijuana in a form for smoking must be packaged in a sealed receptacle with a legible and prominent warning to keep away from children and a warning that states marijuana smoke contains carcinogens and may

negatively affect health. Such receptacles for marijuana in a form for smoking must be plain, opaque, and white without depictions of the product or images other than the medical marijuana treatment center's department-approved logo and the marijuana universal symbol.

14. The department shall adopt rules to regulate the types, appearance, and labeling of marijuana delivery devices dispensed from a medical marijuana treatment center. The rules must require marijuana delivery devices to have an appearance consistent with medical use.

15. Each edible must be individually sealed in plain, opaque wrapping marked only with the marijuana universal symbol. Where practical, each edible must be marked with the marijuana universal symbol. In addition to the packaging and labeling requirements in subparagraphs 11. and 12., edible receptacles must be plain, opaque, and white without depictions of the product or images other than the medical marijuana treatment center's department-approved logo and the marijuana universal symbol. The receptacle must also include a list of all the edible's ingredients, storage instructions, an expiration date, a legible and prominent warning to keep away from children and pets, and a warning that the edible has not been produced or inspected pursuant to federal food safety laws.

16. When dispensing marijuana or a marijuana delivery device, a medical marijuana treatment center:

476 a. May dispense any active, valid order for low-THC
477 cannabis, medical cannabis and cannabis delivery devices issued
478 pursuant to former s. 381.986, Florida Statutes 2016, which was
479 entered into the medical marijuana use registry before July 1,
480 2017.

481 b. May not dispense more than a 70-day supply of marijuana
482 within any 70-day period to a qualified patient or caregiver.
483 May not dispense more than one 35-day supply of marijuana in a
484 form for smoking within any 35-day period to a qualified patient
485 or caregiver. A 35-day supply of marijuana in a form for smoking
486 may not exceed 2.5 ounces unless an exception to this amount is
487 approved by the department pursuant to paragraph (4)(f).

488 c. Must have the medical marijuana treatment center's
489 employee who dispenses the marijuana or a marijuana delivery
490 device enter into the medical marijuana use registry his or her
491 name or unique employee identifier.

492 d. Must verify that the qualified patient and the
493 caregiver, if applicable, each have an active registration in
494 the medical marijuana use registry and an active and valid
495 medical marijuana use registry identification card, the amount
496 and type of marijuana dispensed matches the physician
497 certification in the medical marijuana use registry for that
498 qualified patient, and the physician certification has not
499 already been filled.

500 e. May not dispense marijuana to a qualified patient who

501 is younger than 18 years of age. If the qualified patient is
502 younger than 18 years of age, marijuana may only be dispensed to
503 the qualified patient's caregiver.

504 f. May not dispense or sell any other type of cannabis,
505 alcohol, or illicit drug-related product, including pipes or
506 wrapping papers made with tobacco or hemp, other than a
507 marijuana delivery device required for the medical use of
508 marijuana and which is specified in a physician certification.

509 g. Must, upon dispensing the marijuana or marijuana
510 delivery device, record in the registry the date, time,
511 quantity, and form of marijuana dispensed; the type of marijuana
512 delivery device dispensed; and the name and medical marijuana
513 use registry identification number of the qualified patient or
514 caregiver to whom the marijuana delivery device was dispensed.

515 h. Must ensure that patient records are not visible to
516 anyone other than the qualified patient, his or her caregiver,
517 and authorized medical marijuana treatment center employees.

518 (f) To ensure the safety and security of premises where
519 the cultivation, processing, storing, or dispensing of marijuana
520 occurs, and to maintain adequate controls against the diversion,
521 theft, and loss of marijuana or marijuana delivery devices, a
522 medical marijuana treatment center shall:

523 1.a. Maintain a fully operational security alarm system
524 that secures all entry points and perimeter windows and is
525 equipped with motion detectors; pressure switches; and duress,

526 | panic, and hold-up alarms; and

527 | b. Maintain a video surveillance system that records
528 | continuously 24 hours a day and meets the following criteria:

529 | (I) Cameras are fixed in a place that allows for the clear
530 | identification of persons and activities in controlled areas of
531 | the premises. Controlled areas include grow rooms, processing
532 | rooms, storage rooms, disposal rooms or areas, and point-of-sale
533 | rooms.

534 | (II) Cameras are fixed in entrances and exits to the
535 | premises, which must ~~shall~~ record from both indoor and outdoor,
536 | or ingress and egress, vantage points.

537 | (III) Recorded images must clearly and accurately display
538 | the time and date.

539 | (IV) Retain video surveillance recordings for at least 45
540 | days or longer upon the request of a law enforcement agency.

541 | 2. Ensure that the medical marijuana treatment center's
542 | outdoor premises have sufficient lighting from dusk until dawn.

543 | 3. Ensure that the indoor premises where dispensing occurs
544 | includes a waiting area with sufficient space and seating to
545 | accommodate qualified patients and caregivers and at least one
546 | private consultation area that is isolated from the waiting area
547 | and area where dispensing occurs. A medical marijuana treatment
548 | center may not display products or dispense marijuana or
549 | marijuana delivery devices in the waiting area.

550 | 4. Not dispense from its premises marijuana or a marijuana

551 delivery device between the hours of 9 p.m. and 7 a.m., but may
552 perform all other operations and deliver marijuana to qualified
553 patients 24 hours a day.

554 5. Store marijuana in a secured, locked room or a vault.

555 6. Require at least two of its employees, or two employees
556 of a security agency with whom it contracts, to be on the
557 premises at all times where cultivation, processing, or storing
558 of marijuana occurs.

559 7. Require each employee or contractor to wear a photo
560 identification badge at all times while on the premises.

561 8. Require each visitor to wear a visitor pass at all
562 times while on the premises.

563 9. Implement an alcohol and drug-free workplace policy.

564 10. Report to local law enforcement and notify the
565 department through e-mail within 24 hours after the medical
566 marijuana treatment center is notified or becomes aware of any
567 actual or attempted ~~the~~ theft, diversion, or loss of marijuana.

568 Section 5. Paragraph (d) of subsection (1) of section
569 381.988, Florida Statutes, is amended to read:

570 381.988 Medical marijuana testing laboratories; marijuana
571 tests conducted by a certified laboratory.—

572 (1) A person or entity seeking to be a certified marijuana
573 testing laboratory must:

574 (d) Require all employees, owners, and managers to submit
575 to and pass a level 2 background screening pursuant to chapter

435. The department shall deny certification if the person or entity seeking certification has a disqualifying offense as provided in s. 435.04 or has an arrest awaiting final disposition for, has been found guilty of, or has entered a plea of guilty or nolo contendere to, regardless of adjudication, any offense listed in chapter 837, chapter 895, or chapter 896 or similar law of another jurisdiction. Exemptions from disqualification as provided under s. 435.07 do not apply to this paragraph.

1. As used in this paragraph, the term:

a. "Employee" means any person whose duties or activities involve any aspect of regulatory compliance testing or research and development testing of marijuana for a certified marijuana testing laboratory, regardless of whether such person is compensated for his or her work.

b. "Manager" means any person with authority to exercise or contribute to the operational control, direction, or management of an applicant or certified marijuana testing laboratory or who has authority to supervise any employee of an applicant or a certified marijuana testing laboratory. The term includes an individual with the power or authority to direct or influence the direction or operation of an applicant or a certified marijuana testing laboratory through board membership, an agreement, or a contract.

c. "Owner" means any person who owns or controls a 5

601 percent or greater share of interests of the applicant or a
602 certified marijuana testing laboratory which include beneficial
603 or voting rights to interests. In the event that one person owns
604 a beneficial right to interests and another person holds the
605 voting rights with respect to such interests, then in such case,
606 both are considered the owner of such interests.

607 2. Such employees, owners, and managers must submit a full
608 set of fingerprints to the department or to a vendor, entity, or
609 agency authorized by s. 943.053(13). The department, vendor,
610 entity, or agency shall forward the fingerprints to the
611 Department of Law Enforcement for state processing, and the
612 Department of Law Enforcement shall forward the fingerprints to
613 the Federal Bureau of Investigation for national processing.

614 3.2. Fees for state and federal fingerprint processing and
615 retention must ~~shall~~ be borne by the certified marijuana testing
616 laboratory. The state cost for fingerprint processing is ~~shall~~
617 ~~be~~ as provided in s. 943.053(3)(e) for records provided to
618 persons or entities other than those specified as exceptions
619 therein.

620 4.3. Fingerprints submitted to the Department of Law
621 Enforcement pursuant to this paragraph must ~~shall~~ be retained by
622 the Department of Law Enforcement as provided in s. 943.05(2)(g)
623 and (h) and, when the Department of Law Enforcement begins
624 participation in the program, enrolled in the Federal Bureau of
625 Investigation's national retained print arrest notification

626 program. Any arrest record identified must ~~shall~~ be reported to
627 the department.

628 Section 6. Paragraphs (a) and (c) of subsection (2) of
629 section 456.0145, Florida Statutes, are amended to read:

630 456.0145 Mobile Opportunity by Interstate Licensure
631 Endorsement (MOBILE) Act.—

632 (2) LICENSURE BY ENDORSEMENT.—

633 (a) An applicable board, or the department if there is no
634 board, shall issue a license to practice in this state to an
635 applicant who meets all of the following criteria:

636 1. Submits a complete application.

637 2. Holds an active, unencumbered license issued by another
638 state, the District of Columbia, or a territory of the United
639 States in a profession with a similar scope of practice, as
640 determined by the board or department, as applicable. The term
641 "scope of practice" means the full spectrum of functions,
642 procedures, actions, and services that a health care
643 practitioner is deemed competent and authorized to perform under
644 a license issued in this state.

645 3.a. Has obtained a passing score on a national licensure
646 examination or holds a national certification recognized by the
647 board, or the department if there is no board, as applicable to
648 the profession for which the applicant is seeking licensure in
649 this state; or

650 b. Meets the requirements of paragraph (b).

651 4. Has actively practiced the profession for which the
652 applicant is applying for at least 2 ~~3~~ years during the 4-year
653 period immediately preceding the date of submission of the
654 application.

655 5. Attests that he or she is not, at the time of
656 submission of the application, the subject of a disciplinary
657 proceeding in a jurisdiction in which he or she holds a license
658 or by the United States Department of Defense for reasons
659 related to the practice of the profession for which he or she is
660 applying.

661 6. Has not had disciplinary action taken against him or
662 her in the 5 years immediately preceding the date of submission
663 of the application.

664 7. Meets the financial responsibility requirements of s.
665 456.048 or the applicable practice act, if required for the
666 profession for which the applicant is seeking licensure.

667 8. Submits a set of fingerprints for a background
668 screening pursuant to s. 456.0135, if required for the
669 profession for which he or she is applying.

670
671 The department shall verify information submitted by the
672 applicant under this subsection using the National Practitioner
673 Data Bank, as applicable.

674 (c) A person is ineligible for a license under this
675 section if he or she:

676 1. Has a complaint, an allegation, or an investigation
677 pending before a licensing entity in another state, the District
678 of Columbia, or a possession or territory of the United States;

679 2. Has been convicted of or pled nolo contendere to,
680 regardless of adjudication, any felony or misdemeanor related to
681 the practice of a health care profession;

682 3. Has had a health care provider license revoked or
683 suspended by another state, the District of Columbia, or a
684 territory of the United States, or has voluntarily surrendered
685 any such license in lieu of having disciplinary action taken
686 against the license; or

687 4. Has been reported to the National Practitioner Data
688 Bank, unless the applicant has successfully appealed to have his
689 or her name removed from the data bank. If the reported adverse
690 action was a result of conduct that would not constitute a
691 violation of any law or rule in this state, the board, or the
692 department if there is no board, may:

693 a. Approve the application;

694 b. Approve the application with restrictions on the scope
695 of practice of the licensee;

696 c. Approve the application with placement of the licensee
697 on probation for a period of time and subject to such conditions
698 as the board, or the department if there is no board, may
699 specify, including, but not limited to, requiring the applicant
700 to submit to treatment, attend continuing education courses, or

submit to reexamination; or

d. Deny the application.

Section 7. Paragraph (d) of subsection (1) and subsection (3) of section 456.44, Florida Statutes, are amended to read:

456.44 Controlled substance prescribing.—

(1) DEFINITIONS.—As used in this section, the term:

(d) "Board-certified pain management physician" means a physician who possesses board certification in pain medicine by the American Board of Pain Medicine, board certification by the American Board of Interventional Pain Physicians, or board certification or subcertification in pain management or pain medicine by a specialty board recognized by the American Board of Physician Specialties ~~American Association of Physician Specialists~~ or the American Board of Medical Specialties or an osteopathic physician who holds a certificate in Pain Management by the American Osteopathic Association.

(3) STANDARDS OF PRACTICE FOR TREATMENT OF CHRONIC NONMALIGNANT PAIN.—The standards of practice in this section do not supersede the level of care, skill, and treatment recognized in general law related to health care licensure.

(a) A complete medical history and a physical examination must be conducted before beginning any treatment and must be documented in the medical record. The exact components of the physical examination shall be left to the judgment of the registrant who is expected to perform a physical examination

726 proportionate to the diagnosis that justifies a treatment. The
727 medical record must, at a minimum, document the nature and
728 intensity of the pain, current and past treatments for pain,
729 underlying or coexisting diseases or conditions, the effect of
730 the pain on physical and psychological function, a review of
731 previous medical records, previous diagnostic studies, and
732 history of alcohol and substance abuse. The medical record shall
733 also document the presence of one or more recognized medical
734 indications for the use of a controlled substance. Each
735 registrant must develop a written plan for assessing each
736 patient's risk of aberrant drug-related behavior, which may
737 include patient drug testing. Registrants must assess each
738 patient's risk for aberrant drug-related behavior and monitor
739 that risk on an ongoing basis in accordance with the plan.

740 (b) Each registrant must develop a written individualized
741 treatment plan for each patient. The treatment plan shall state
742 objectives that will be used to determine treatment success,
743 such as pain relief and improved physical and psychosocial
744 function, and shall indicate if any further diagnostic
745 evaluations or other treatments are planned. After treatment
746 begins, the registrant shall adjust drug therapy to the
747 individual medical needs of each patient. Other treatment
748 modalities, including a rehabilitation program, shall be
749 considered depending on the etiology of the pain and the extent
750 to which the pain is associated with physical and psychosocial

751 impairment. The interdisciplinary nature of the treatment plan
752 shall be documented.

753 (c) The registrant shall discuss the risks and benefits of
754 the use of controlled substances, including the risks of abuse
755 and addiction, as well as physical dependence and its
756 consequences, with the patient, persons designated by the
757 patient, or the patient's surrogate or guardian if the patient
758 is incompetent. The registrant shall use a written controlled
759 substance agreement between the registrant and the patient
760 outlining the patient's responsibilities, including, but not
761 limited to:

762 1. Number and frequency of controlled substance
763 prescriptions and refills.

764 2. Patient compliance and reasons for which drug therapy
765 may be discontinued, such as a violation of the agreement.

766 3. An agreement that controlled substances for the
767 treatment of chronic nonmalignant pain shall be prescribed by a
768 single treating registrant unless otherwise authorized by the
769 treating registrant and documented in the medical record.

770 (d) The patient shall be seen by the registrant at regular
771 intervals, not to exceed 3 months, to assess the efficacy of
772 treatment, ensure that controlled substance therapy remains
773 indicated, evaluate the patient's progress toward treatment
774 objectives, consider adverse drug effects, and review the
775 etiology of the pain. Continuation or modification of therapy

776 shall depend on the registrant's evaluation of the patient's
777 progress. If treatment goals are not being achieved, despite
778 medication adjustments, the registrant shall reevaluate the
779 appropriateness of continued treatment. The registrant shall
780 monitor patient compliance in medication usage, related
781 treatment plans, controlled substance agreements, and
782 indications of substance abuse or diversion at a minimum of 3-
783 month intervals.

784 (e) The registrant shall refer the patient as necessary
785 for additional evaluation and treatment in order to achieve
786 treatment objectives. Special attention shall be given to those
787 patients who are at risk for misusing their medications and
788 those whose living arrangements pose a risk for medication
789 misuse or diversion. The management of pain in patients with a
790 history of substance abuse or with a comorbid psychiatric
791 disorder requires extra care, monitoring, and documentation and
792 requires consultation with or referral to an addiction medicine
793 specialist or a psychiatrist.

794 (f) A registrant must maintain accurate, current, and
795 complete records that are accessible and readily available for
796 review and comply with the requirements of this section, the
797 applicable practice act, and applicable board rules. The medical
798 records must include, but are not limited to:

799 1. The complete medical history and a physical
800 examination, including history of drug abuse or dependence.

2. Diagnostic, therapeutic, and laboratory results.
 3. Evaluations and consultations.
 4. Treatment objectives.
 5. Discussion of risks and benefits.
 6. Treatments.
 7. Medications, including date, type, dosage, and quantity prescribed.
 8. Instructions and agreements.
 9. Periodic reviews.
 10. Results of any drug testing.
 11. A photocopy of the patient's government-issued photo identification.
 12. If a written prescription for a controlled substance is given to the patient, a duplicate of the prescription.
 13. The registrant's full name presented in a legible manner.
- (g) A registrant shall immediately refer patients with signs or symptoms of substance abuse to a board-certified pain management physician, an addiction medicine specialist, or a mental health addiction facility as it pertains to drug abuse or addiction unless the registrant is a physician who is board-certified or board-eligible in pain management. Throughout the period of time before receiving the consultant's report, a prescribing registrant shall clearly and completely document medical justification for continued treatment with controlled

substances and those steps taken to ensure medically appropriate use of controlled substances by the patient. Upon receipt of the consultant's written report, the prescribing registrant shall incorporate the consultant's recommendations for continuing, modifying, or discontinuing controlled substance therapy. The resulting changes in treatment shall be specifically documented in the patient's medical record. Evidence or behavioral indications of diversion shall be followed by discontinuation of controlled substance therapy, and the patient shall be discharged, and all results of testing and actions taken by the registrant shall be documented in the patient's medical record.

This subsection does not apply to a board-eligible or board-certified anesthesiologist, physiatrist, rheumatologist, or neurologist, or to a board-certified physician who has surgical privileges at a hospital or ambulatory surgery center and primarily provides surgical services. This subsection does not apply to a board-eligible or board-certified medical specialist who has also completed a fellowship in pain medicine approved by the Accreditation Council for Graduate Medical Education or the American Osteopathic Association, or who is board eligible or board certified in pain medicine by the American Board of Pain Medicine, the American Board of Interventional Pain Physicians, the American Board of Physician Specialties ~~American Association of Physician Specialists~~, or a board approved by the American

Board of Medical Specialties or the American Osteopathic Association and performs interventional pain procedures of the type routinely billed using surgical codes. This subsection does not apply to a registrant who prescribes medically necessary controlled substances for a patient during an inpatient stay in a hospital licensed under chapter 395.

Section 8. Section 458.313, Florida Statutes, is amended to read:

458.313 Licensure by endorsement; requirements; fees.—The department shall issue a license by endorsement to any applicant who, upon applying to the department on forms furnished by the department and remitting a fee set by the board in an amount not to exceed \$500, the board certifies has:

(1) Met the requirements for licensure by endorsement under s. 456.0145; or

(2) Met the requirements for licensure by endorsement under s. 456.0145 except for s. 456.0145(2)(a)4. but has submitted evidence to the board's satisfaction of the successful completion of either a board-approved postgraduate training program within 2 years preceding the filing of an application or a board-approved clinical competency examination within the year preceding the filing of an application.

Section 9. Paragraph (i) of subsection (1) of section 458.3145, Florida Statutes, is amended to read:

458.3145 Medical faculty certificate.—

876 (1) A medical faculty certificate may be issued without
877 examination to an individual who meets all of the following
878 criteria:

879 (i) Has been offered and has accepted a full-time faculty
880 appointment to teach in a program of medicine at any of the
881 following institutions:

- 882 1. The University of Florida.
- 883 2. The University of Miami.
- 884 3. The University of South Florida.
- 885 4. The Florida State University.
- 886 5. The Florida International University.
- 887 6. The University of Central Florida.
- 888 7. The Mayo Clinic College of Medicine and Science in
889 Jacksonville, Florida.
- 890 8. The Florida Atlantic University.
- 891 9. The Johns Hopkins All Children's Hospital in St.
892 Petersburg, Florida.
- 893 10. Nova Southeastern University.
- 894 11. Lake Erie College of Osteopathic Medicine in
895 Bradenton, Florida.
- 896 12. Burrell College of Osteopathic Medicine in Melbourne,
897 Florida.
- 898 13. The Orlando College of Osteopathic Medicine.
- 899 14. Lincoln Memorial University-DeBusk College of
900 Osteopathic Medicine in Orange Park, Florida.

901 15. Loma Linda University School of Medicine -
902 AdventHealth regional campuses in Orlando, Florida.

903 Section 10. Subsection (1) of section 458.315, Florida
904 Statutes, is amended to read:

905 458.315 Temporary certificate for practice in areas of
906 critical need.—

907 (1) A physician ~~or physician assistant who is~~ licensed to
908 practice in any jurisdiction of the United States ~~and~~ whose
909 license is currently valid may be issued a temporary certificate
910 for practice in areas of critical need. A physician seeking such
911 certificate must pay an application fee of \$300. A physician
912 assistant licensed to practice in any state of the United States
913 or the District of Columbia whose license is currently valid may
914 be issued a temporary certificate for practice in areas of
915 critical need.

916 Section 11. Subsection (1) of section 459.0076, Florida
917 Statutes, is amended to read:

918 459.0076 Temporary certificate for practice in areas of
919 critical need.—

920 (1) A physician ~~or physician assistant~~ who holds a valid
921 license to practice in any jurisdiction of the United States may
922 be issued a temporary certificate for practice in areas of
923 critical need. A physician seeking such certificate must pay an
924 application fee of \$300. A physician assistant licensed to
925 practice in any state of the United States or the District of

926 Columbia whose license is currently valid may be issued a
927 temporary certificate for practice in areas of critical need.

928 Section 12. Paragraph (a) of subsection (1) of section
929 458.3265, Florida Statutes, is amended to read:

930 458.3265 Pain-management clinics.—

931 (1) REGISTRATION.—

932 (a)1. As used in this section, the term:

933 a. "Board eligible" means successful completion of an
934 anesthesia, physical medicine and rehabilitation, rheumatology,
935 or neurology residency program approved by the Accreditation
936 Council for Graduate Medical Education or the American
937 Osteopathic Association for a period of 6 years from successful
938 completion of such residency program.

939 b. "Chronic nonmalignant pain" means pain unrelated to
940 cancer which persists beyond the usual course of disease or the
941 injury that is the cause of the pain or more than 90 days after
942 surgery.

943 c. "Pain-management clinic" or "clinic" means any publicly
944 or privately owned facility:

945 (I) That advertises in any medium for any type of pain-
946 management services; or

947 (II) Where in any month a majority of patients are
948 prescribed opioids, benzodiazepines, barbiturates, or
949 carisoprodol for the treatment of chronic nonmalignant pain.

950 2. Each pain-management clinic must register with the

951 department or hold a valid certificate of exemption pursuant to
952 subsection (2).

953 3. The following clinics are exempt from the registration
954 requirement of paragraphs (c)-(m) and must apply to the
955 department for a certificate of exemption:

956 a. A clinic licensed as a facility pursuant to chapter
957 395;

958 b. A clinic in which the majority of the physicians who
959 provide services in the clinic primarily provide surgical
960 services;

961 c. A clinic owned by a publicly held corporation whose
962 shares are traded on a national exchange or on the over-the-
963 counter market and whose total assets at the end of the
964 corporation's most recent fiscal quarter exceeded \$50 million;

965 d. A clinic affiliated with an accredited medical school
966 at which training is provided for medical students, residents,
967 or fellows;

968 e. A clinic that does not prescribe controlled substances
969 for the treatment of pain;

970 f. A clinic owned by a corporate entity exempt from
971 federal taxation under 26 U.S.C. s. 501(c)(3);

972 g. A clinic wholly owned and operated by one or more
973 board-eligible or board-certified anesthesiologists,
974 physiatrists, rheumatologists, or neurologists; or

975 h. A clinic wholly owned and operated by a physician

976 multispecialty practice where one or more board-eligible or
977 board-certified medical specialists, who have also completed
978 fellowships in pain medicine approved by the Accreditation
979 Council for Graduate Medical Education or who are also board-
980 certified in pain medicine by the American Board of Pain
981 Medicine or a board approved by the American Board of Medical
982 Specialties, the American Board of Physician Specialties
983 ~~American Association of Physician Specialists~~, or the American
984 Osteopathic Association, perform interventional pain procedures
985 of the type routinely billed using surgical codes.

986 Section 13. Paragraph (a) of subsection (1) of section
987 458.3475, Florida Statutes, is amended to read:

988 458.3475 Anesthesiologist assistants.—

989 (1) DEFINITIONS.—As used in this section, the term:

990 (a) "Anesthesiologist" means an allopathic physician who
991 holds an active, unrestricted license; who has successfully
992 completed an anesthesiology training program approved by the
993 Accreditation Council on Graduate Medical Education or its
994 equivalent; and who is certified by the American Board of
995 Anesthesiology, is eligible to take that board's examination, or
996 is certified by the Board of Certification in Anesthesiology
997 affiliated with the American Board of Physician Specialties
998 ~~American Association of Physician Specialists~~.

999 Section 14. Paragraph (a) of subsection (1) of section
1000 459.0137, Florida Statutes, is amended to read:

459.0137 Pain-management clinics.—

(1) REGISTRATION.—

(a)1. As used in this section, the term:

a. "Board eligible" means successful completion of an anesthesia, physical medicine and rehabilitation, rheumatology, or neurology residency program approved by the Accreditation Council for Graduate Medical Education or the American Osteopathic Association for a period of 6 years from successful completion of such residency program.

b. "Chronic nonmalignant pain" means pain unrelated to cancer which persists beyond the usual course of disease or the injury that is the cause of the pain or more than 90 days after surgery.

c. "Pain-management clinic" or "clinic" means any publicly or privately owned facility:

(I) That advertises in any medium for any type of pain-management services; or

(II) Where in any month a majority of patients are prescribed opioids, benzodiazepines, barbiturates, or carisoprodol for the treatment of chronic nonmalignant pain.

2. Each pain-management clinic must register with the department or hold a valid certificate of exemption pursuant to subsection (2).

3. The following clinics are exempt from the registration requirement of paragraphs (c)-(m) and must apply to the

department for a certificate of exemption:

a. A clinic licensed as a facility pursuant to chapter 395;

b. A clinic in which the majority of the physicians who provide services in the clinic primarily provide surgical services;

c. A clinic owned by a publicly held corporation whose shares are traded on a national exchange or on the over-the-counter market and whose total assets at the end of the corporation's most recent fiscal quarter exceeded \$50 million;

d. A clinic affiliated with an accredited medical school at which training is provided for medical students, residents, or fellows;

e. A clinic that does not prescribe controlled substances for the treatment of pain;

f. A clinic owned by a corporate entity exempt from federal taxation under 26 U.S.C. s. 501(c)(3);

g. A clinic wholly owned and operated by one or more board-eligible or board-certified anesthesiologists, physiatrists, rheumatologists, or neurologists; or

h. A clinic wholly owned and operated by a physician multispecialty practice where one or more board-eligible or board-certified medical specialists, who have also completed fellowships in pain medicine approved by the Accreditation Council for Graduate Medical Education or the American

Osteopathic Association or who are also board-certified in pain medicine by the American Board of Pain Medicine or a board approved by the American Board of Medical Specialties, the American Board of Physician Specialties ~~American Association of Physician Specialists~~, or the American Osteopathic Association, perform interventional pain procedures of the type routinely billed using surgical codes.

Section 15. Paragraph (a) of subsection (1) of section 459.023, Florida Statutes, is amended to read:

459.023 Anesthesiologist assistants.—

(1) DEFINITIONS.—As used in this section, the term:

(a) "Anesthesiologist" means an osteopathic physician who holds an active, unrestricted license; who has successfully completed an anesthesiology training program approved by the Accreditation Council on Graduate Medical Education, or its equivalent, or the American Osteopathic Association; and who is certified by the American Osteopathic Board of Anesthesiology or is eligible to take that board's examination, is certified by the American Board of Anesthesiology or is eligible to take that board's examination, or is certified by the Board of Certification in Anesthesiology affiliated with the American Board of Physician Specialties ~~American Association of Physician Specialists~~.

Section 16. Section 486.112, Florida Statutes, is amended to read:

1076 486.112 Physical Therapy Licensure Compact.—The Physical
1077 Therapy Licensure Compact is hereby enacted into law and entered
1078 into by this state with all other jurisdictions legally joining
1079 therein in the form substantially as follows:

1081 ARTICLE I

1082 PURPOSE AND OBJECTIVES

1083
1084 (1) The purpose of the compact is to facilitate interstate
1085 practice of physical therapy with the goal of improving public
1086 access to physical therapy services. The compact preserves the
1087 regulatory authority of member states to protect public health
1088 and safety through their current systems of state licensure. For
1089 purposes of state regulation under the compact, the practice of
1090 physical therapy is deemed to have occurred in the state where
1091 the patient is located at the time physical therapy is provided
1092 to the patient.

1093 (2) The compact is designed to achieve all of the
1094 following objectives:

1095 (a) Increase public access to physical therapy services by
1096 providing for the mutual recognition of other member state
1097 licenses.

1098 (b) Enhance the states' ability to protect the public's
1099 health and safety.

1100 (c) Encourage the cooperation of member states in

1101 regulating multistate physical therapy practice.

1102 (d) Support spouses of relocating military members.

1103 (e) Enhance the exchange of licensure, investigative, and
1104 disciplinary information between member states.

1105 (f) Allow a remote state to hold a provider of services
1106 with a compact privilege in that state accountable to that
1107 state's practice standards.

1108
1109 ARTICLE II

1110 DEFINITIONS

1111
1112 As used in the compact, and except as otherwise provided,
1113 the term:

1114 (1) "Active duty military" means full-time duty status in
1115 the active uniformed service of the United States, including
1116 members of the National Guard and Reserve on active duty orders
1117 pursuant to 10 U.S.C. chapter 1209 or chapter 1211.

1118 (2) "Adverse action" means disciplinary action taken by a
1119 physical therapy licensing board based upon misconduct,
1120 unacceptable performance, or a combination of both.

1121 (3) "Alternative program" means a nondisciplinary
1122 monitoring or practice remediation process approved by a state's
1123 physical therapy licensing board. The term includes, but is not
1124 limited to, programs that address substance abuse issues.

1125 (4) "Compact privilege" means the authorization granted by

1126 a remote state to allow a licensee from another member state to
1127 practice as a physical therapist or physical therapist assistant
1128 in the remote state under its laws and rules.

1129 (5) "Continuing competence" means a requirement, as a
1130 condition of license renewal, to provide evidence of
1131 participation in, and completion of, educational and
1132 professional activities relevant to the practice of physical
1133 therapy.

1134 (6) "Data system" means the coordinated database and
1135 reporting system created by the Physical Therapy Compact
1136 Commission for the exchange of information between member states
1137 relating to licensees or applicants under the compact, including
1138 identifying information, licensure data, investigative
1139 information, adverse actions, nonconfidential information
1140 related to alternative program participation, any denials of
1141 applications for licensure, and other information as specified
1142 by commission rule.

1143 (7) "Encumbered license" means a license that a physical
1144 therapy licensing board has limited in any way.

1145 (8) "Executive board" means a group of directors elected
1146 or appointed to act on behalf of, and within the powers granted
1147 to them by, the commission.

1148 (9) "Home state" means the member state that is the
1149 licensee's primary state of residence.

1150 (10) "Investigative information" means information,

1151 records, and documents received or generated by a physical
1152 therapy licensing board pursuant to an investigation.

1153 (11) "Jurisprudence requirement" means the assessment of
1154 an individual's knowledge of the laws and rules governing the
1155 practice of physical therapy in a specific state.

1156 (12) "Licensee" means an individual who currently holds an
1157 authorization from a state to practice as a physical therapist
1158 or physical therapist assistant.

1159 (13) "Member state" means a state that has enacted the
1160 compact.

1161 (14) "Party state" means any member state in which a
1162 licensee holds a current license or compact privilege or is
1163 applying for a license or compact privilege.

1164 (15) "Physical therapist" means an individual licensed by
1165 a state to practice physical therapy.

1166 (16) ~~(15)~~ "Physical therapist assistant" means an
1167 individual licensed by a state to assist a physical therapist in
1168 specified areas of physical therapy.

1169 (17) ~~(16)~~ "Physical therapy" or "the practice of physical
1170 therapy" means the care and services provided by or under the
1171 direction and supervision of a licensed physical therapist.

1172 (18) ~~(17)~~ "Physical Therapy Compact Commission" or
1173 "commission" means the national administrative body whose
1174 membership consists of all states that have enacted the compact.

1175 (19) ~~(18)~~ "Physical therapy licensing board" means the

1176 agency of a state which is responsible for the licensing and
1177 regulation of physical therapists and physical therapist
1178 assistants.

1179 (20)~~(19)~~ "Remote state" means a member state other than
1180 the home state where a licensee is exercising or seeking to
1181 exercise the compact privilege.

1182 (21)~~(20)~~ "Rule" means a regulation, principle, or
1183 directive adopted by the commission which has the force of law.

1184 (22)~~(21)~~ "State" means any state, commonwealth, district,
1185 or territory of the United States of America which regulates the
1186 practice of physical therapy.

1187
1188 ARTICLE III

1189 STATE PARTICIPATION IN THE COMPACT
1190

1191 (1) To participate in the compact, a state must do all of
1192 the following:

1193 (a) Participate fully in the commission's data system,
1194 including using the commission's unique identifier, as defined
1195 by commission rule.

1196 (b) Have a mechanism in place for receiving and
1197 investigating complaints about licensees.

1198 (c) Notify the commission, in accordance with the terms of
1199 the compact and rules, of any adverse action or the availability
1200 of investigative information regarding a licensee.

(d) Fully implement a criminal background check requirement, within a timeframe established by commission rule, which uses results from the Federal Bureau of Investigation record search on criminal background checks to make licensure decisions in accordance with subsection (2).

(e) Comply with the commission's rules.

(f) Use a recognized national examination as a requirement for licensure pursuant to the commission's rules.

(g) Have continuing competence requirements as a condition for license renewal.

(2) Upon adoption of the compact, a member state has the authority to obtain biometric-based information from each licensee applying for a compact privilege and submit this information to the Federal Bureau of Investigation for a criminal background check in accordance with 28 U.S.C. s. 534 and 34 U.S.C. s. 40316.

(3) A member state must grant the compact privilege to a licensee holding a valid unencumbered license in another member state in accordance with the terms of the compact and rules.

ARTICLE IV

COMPACT PRIVILEGE

(1) To exercise the compact privilege under the compact, a licensee must satisfy all of the following conditions:

1226 (a) Hold a license in the home state.

1227 (b) Not have an encumbrance on any state license.

1228 (c) Be eligible for a compact privilege in all member
1229 states in accordance with subsections (4), (7), and (8).

1230 (d) Not have had an adverse action against any license or
1231 compact privilege within the preceding 2 years.

1232 (e) Notify the commission that the licensee is seeking the
1233 compact privilege within a remote state.

1234 (f) Meet any jurisprudence requirements established by the
1235 remote state in which the licensee is seeking a compact
1236 privilege.

1237 (g) Report to the commission adverse action taken by any
1238 nonmember state within 30 days after the date the adverse action
1239 is taken.

1240 (2) The compact privilege is valid until the expiration
1241 date of the home license. The licensee must continue to meet the
1242 requirements of subsection (1) to maintain the compact privilege
1243 in a remote state.

1244 (3) A licensee providing physical therapy in a remote
1245 state under the compact privilege must comply with the laws and
1246 rules of the remote state.

1247 (4) A licensee providing physical therapy in a remote
1248 state is subject to that state's regulatory authority. A remote
1249 state may, in accordance with due process and that state's laws,
1250 remove a licensee's compact privilege in the remote state for a

specific period of time, impose fines, and take any other necessary actions to protect the health and safety of its citizens. The licensee is not eligible for a compact privilege in any member state until the specific period of time for removal has ended and all fines are paid.

(5) If a home state license is encumbered, the licensee loses the compact privilege in any remote state until the following conditions are met:

(a) The home state license is no longer encumbered.

(b) Two years have elapsed from the date of the adverse action.

(6) Once an encumbered license in the home state is restored to good standing, the licensee must meet the requirements of subsection (1) to obtain a compact privilege in any remote state.

(7) If a licensee's compact privilege in any remote state is removed, the licensee loses the compact privilege in all remote states until all of the following conditions are met:

(a) The specific period of time for which the compact privilege was removed has ended.

(b) All fines have been paid.

(c) Two years have elapsed from the date of the adverse action.

(8) Once the requirements of subsection (7) have been met, the licensee must meet the requirements of subsection (1) to

1276 obtain a compact privilege in a remote state.

1278 ARTICLE V

1279 ACTIVE DUTY MILITARY PERSONNEL

1280 AND THEIR SPOUSES

1281
1282 A licensee who is active duty military or is the spouse of
1283 an individual who is active duty military may choose any of the
1284 following locations to designate his or her home state:

1285 (1) Home of record.

1286 (2) Permanent change of station location.

1287 (3) State of current residence, if it is different from
1288 the home of record or permanent change of station location.

1289
1290 ARTICLE VI

1291 ADVERSE ACTIONS

1292
1293 (1) A home state has exclusive power to impose adverse
1294 action against a license issued by the home state.

1295 (2) A home state may take adverse action based on the
1296 investigative information of a remote state, so long as the home
1297 state follows its own procedures for imposing adverse action.

1298 (3) The compact does not override a member state's
1299 decision that participation in an alternative program may be
1300 used in lieu of adverse action and that such participation

1301 remain nonpublic if required by the member state's laws. Member
1302 states must require licensees who enter any alternative programs
1303 in lieu of discipline to agree not to practice in any other
1304 member state during the term of the alternative program without
1305 prior authorization from such other member state.

1306 (4) A member state may investigate actual or alleged
1307 violations of the laws and rules for the practice of physical
1308 therapy committed in any other member state by a physical
1309 therapist or physical therapist assistant practicing under the
1310 compact who holds a license or compact privilege in such other
1311 member state.

1312 (5) A remote state may do any of the following:

1313 (a) Take adverse actions as set forth in subsection (4) of
1314 Article IV against a licensee's compact privilege in the state.

1315 (b) Issue subpoenas for both hearings and investigations
1316 which require the attendance and testimony of witnesses and the
1317 production of evidence. Subpoenas issued by a physical therapy
1318 licensing board in a party ~~member~~ state for the attendance and
1319 testimony of witnesses or for the production of evidence from
1320 another party ~~member~~ state must be enforced in the latter state
1321 by any court of competent jurisdiction, according to the
1322 practice and procedure of that court applicable to subpoenas
1323 issued in proceedings pending before it. The issuing authority
1324 shall pay any witness fees, travel expenses, mileage, and other
1325 fees required by the service laws of the state where the

witnesses or evidence is located.

(c) If otherwise permitted by state law, recover from the licensee the costs of investigations and disposition of cases resulting from any adverse action taken against that licensee.

(6)(a) In addition to the authority granted to a member state by its respective physical therapy practice act or other applicable state law, a member state may participate with other member states in joint investigations of licensees.

(b) Member states shall share any investigative, litigation, or compliance materials in furtherance of any joint or individual investigation initiated under the compact.

ARTICLE VII

ESTABLISHMENT OF THE PHYSICAL THERAPY COMPACT COMMISSION

(1) COMMISSION CREATED.—The member states hereby create and establish a joint public agency known as the Physical Therapy Compact Commission:

(a) The commission is an instrumentality of the member states.

(b) Venue is proper, and judicial proceedings by or against the commission must be brought solely and exclusively, in a court of competent jurisdiction where the principal office of the commission is located. The commission may waive venue and

jurisdictional defenses to the extent it adopts or consents to participate in alternative dispute resolution proceedings.

(c) The compact may not be construed to be a waiver of sovereign immunity.

(2) MEMBERSHIP, VOTING, AND MEETINGS.—

(a) Each member state has and is limited to one delegate selected by that member state's physical therapy licensing board to serve on the commission. The delegate must be a current member of the physical therapy licensing board who is a physical therapist, a physical therapist assistant, a public member, or the board administrator.

(b) A delegate may be removed or suspended from office as provided by the law of the state from which the delegate is appointed. Any vacancy occurring on the commission must be filled by the physical therapy licensing board of the member state for which the vacancy exists.

(c) Each delegate is entitled to one vote with regard to the adoption of rules and bylaws and shall otherwise have an opportunity to participate in the business and affairs of the commission.

(d) A delegate shall vote in person or by such other means as provided in the bylaws. The bylaws may provide for delegates' participation in meetings by telephone or other means of communication.

(e) The commission shall meet at least once during each

1376 calendar year. Additional meetings may be held as set forth in
1377 the bylaws.

1378 (f) All meetings must be open to the public, and public
1379 notice of meetings must be given in the same manner as required
1380 under the rulemaking provisions in Article IX.

1381 (g) The commission or the executive board or other
1382 committees of the commission may convene in a closed, nonpublic
1383 meeting if the commission or executive board or other committees
1384 of the commission must discuss any of the following:

1385 1. Noncompliance of a member state with its obligations
1386 under the compact.

1387 2. The employment, compensation, or discipline of, or
1388 other matters, practices, or procedures related to, specific
1389 employees or other matters related to the commission's internal
1390 personnel practices and procedures.

1391 3. Current, threatened, or reasonably anticipated
1392 litigation against the commission, executive board, or other
1393 committees of the commission.

1394 4. Negotiation of contracts for the purchase, lease, or
1395 sale of goods, services, or real estate.

1396 5. An accusation of any person of a crime or a formal
1397 censure of any person.

1398 6. Information disclosing trade secrets or commercial or
1399 financial information that is privileged or confidential.

1400 7. Information of a personal nature where disclosure would

1401 constitute a clearly unwarranted invasion of personal privacy.

1402 8. Investigatory records compiled for law enforcement
1403 purposes.

1404 9. Information related to any investigative reports
1405 prepared by or on behalf of or for use of the commission or
1406 other committee charged with responsibility for investigation or
1407 determination of compliance issues pursuant to the compact.

1408 10. Matters specifically exempted from disclosure by
1409 federal or member state statute.

1410 (h) If a meeting, or portion of a meeting, is closed
1411 pursuant to this subsection, the commission's legal counsel or
1412 designee must certify that the meeting may be closed and must
1413 reference each relevant exempting provision.

1414 (i) The commission shall keep minutes that fully and
1415 clearly describe all matters discussed in a meeting and shall
1416 provide a full and accurate summary of actions taken and the
1417 reasons therefor, including a description of the views
1418 expressed. All documents considered in connection with an action
1419 must be identified in the minutes. All minutes and documents of
1420 a closed meeting must remain under seal, subject to release only
1421 by a majority vote of the commission or order of a court of
1422 competent jurisdiction.

1423 (3) DUTIES.—The commission shall do all of the following:

1424 (a) Establish the fiscal year of the commission.

1425 (b) Establish bylaws.

(c) Maintain its financial records in accordance with the bylaws.

(d) Meet and take such actions as are consistent with the provisions of the compact and the bylaws.

(4) POWERS.—The commission may do any of the following:

(a) Adopt uniform rules to facilitate and coordinate implementation and administration of the compact. The rules have the force and effect of law and are binding in all member states.

(b) Bring and prosecute legal proceedings or actions in the name of the commission, provided that the standing of any state physical therapy licensing board to sue or be sued under applicable law is not affected.

(c) Purchase and maintain insurance and bonds.

(d) Borrow, accept, or contract for services of personnel, including, but not limited to, employees of a member state.

(e) Hire employees and elect or appoint officers; fix the compensation of, define the duties of, and grant appropriate authority to such individuals to carry out the purposes of the compact; and establish the commission's personnel policies and programs relating to conflicts of interest, qualifications of personnel, and other related personnel matters.

(f) Accept any appropriate donations and grants of money, equipment, supplies, materials, and services and receive, use, and dispose of the same, provided that at all times the

commission avoids any appearance of impropriety or conflict of interest.

(g) Lease, purchase, accept appropriate gifts or donations of, or otherwise own, hold, improve, or use any property, real, personal, or mixed, provided that at all times the commission avoids any appearance of impropriety or conflict of interest.

(h) Sell, convey, mortgage, pledge, lease, exchange, abandon, or otherwise dispose of any property, real, personal, or mixed.

(i) Establish a budget and make expenditures.

(j) Borrow money.

(k) Appoint committees, including standing committees composed of members, state regulators, state legislators or their representatives, and consumer representatives, and such other interested persons as may be designated in the compact and the bylaws.

(l) Provide information to, receive information from, and cooperate with law enforcement agencies.

(m) Establish and elect an executive board.

(n) Perform such other functions as may be necessary or appropriate to achieve the purposes of the compact consistent with the state regulation of physical therapy licensure and practice.

(5) THE EXECUTIVE BOARD.—

(a) The executive board may act on behalf of the

1476 commission according to the terms of the compact.

1477 (b) The executive board shall be composed of the following
1478 nine members:

1479 1. Seven voting members who are elected by the commission
1480 from the current membership of the commission.

1481 2. One ex officio, nonvoting member from the recognized
1482 national physical therapy professional association.

1483 3. One ex officio, nonvoting member from the recognized
1484 membership organization of the physical therapy licensing
1485 boards.

1486 (c) The ex officio members shall be selected by their
1487 respective organizations.

1488 (d) The commission may remove any member of the executive
1489 board as provided in its bylaws.

1490 (e) The executive board shall meet at least annually.

1491 (f) The executive board shall do all of the following:

1492 1. Recommend to the entire commission changes to the rules
1493 or bylaws, compact legislation, fees paid by compact member
1494 states, such as annual dues, and any commission compact fee
1495 charged to licensees for the compact privilege.

1496 2. Ensure compact administration services are
1497 appropriately provided, contractually or otherwise.

1498 3. Prepare and recommend the budget.

1499 4. Maintain financial records on behalf of the commission.

1500 5. Monitor compact compliance of member states and provide

1501 compliance reports to the commission.

1502 6. Establish additional committees as necessary.

1503 7. Perform other duties as provided in the rules or
1504 bylaws.

1505 (6) FINANCING OF THE COMMISSION.—

1506 (a) The commission shall pay, or provide for the payment
1507 of, the reasonable expenses of its establishment, organization,
1508 and ongoing activities.

1509 (b) The commission may accept any appropriate revenue
1510 sources, donations, and grants of money, equipment, supplies,
1511 materials, and services.

1512 (c) The commission may levy and collect an annual
1513 assessment from each member state or impose fees on other
1514 parties to cover the cost of the operations and activities of
1515 the commission and its staff. Such assessments and fees must
1516 total to an amount sufficient to cover the commission's annual
1517 budget as approved each year for which revenue is not provided
1518 by other sources. The aggregate annual assessment amount must be
1519 allocated based upon a formula to be determined by the
1520 commission, which shall adopt a rule binding upon all member
1521 states.

1522 (d) The commission may not incur obligations of any kind
1523 before securing the funds adequate to meet such obligations; nor
1524 may the commission pledge the credit of any of the member
1525 states, except by and with the authority of the member state.

1526 (e) The commission shall keep accurate accounts of all
1527 receipts and disbursements. The receipts and disbursements of
1528 the commission are subject to the audit and accounting
1529 procedures established under its bylaws. However, all receipts
1530 and disbursements of funds handled by the commission must be
1531 audited yearly by a certified or licensed public accountant, and
1532 the report of the audit must be included in and become part of
1533 the annual report of the commission.

1534 (7) QUALIFIED IMMUNITY, DEFENSE, AND INDEMNIFICATION.—

1535 (a) The members, officers, executive director, employees,
1536 and representatives of the commission are immune from suit and
1537 liability, whether personally or in their official capacity, for
1538 any claim for damage to or loss of property or personal injury
1539 or other civil liability caused by or arising out of any actual
1540 or alleged act, error, or omission that occurred, or that the
1541 person against whom the claim is made had a reasonable basis for
1542 believing occurred, within the scope of commission employment,
1543 duties, or responsibilities. However, this paragraph may not be
1544 construed to protect any such person from suit or liability for
1545 any damage, loss, injury, or liability caused by the
1546 intentional, willful, or wanton misconduct of that person.

1547 (b) The commission shall defend any member, officer,
1548 executive director, employee, or representative of the
1549 commission in any civil action seeking to impose liability
1550 arising out of any actual or alleged act, error, or omission

1551 that occurred within the scope of commission employment, duties,
1552 or responsibilities, or that the person against whom the claim
1553 is made had a reasonable basis for believing occurred within the
1554 scope of commission employment, duties, or responsibilities.
1555 However, this subsection may not be construed to prohibit any
1556 member, officer, executive director, employee, or representative
1557 of the commission from retaining his or her own counsel or to
1558 require the commission to defend such person if the actual or
1559 alleged act, error, or omission resulted from that person's
1560 intentional, willful, or wanton misconduct.

1561 (c) The commission shall indemnify and hold harmless any
1562 member, officer, executive director, employee, or representative
1563 of the commission for the amount of any settlement or judgment
1564 obtained against that person arising out of any actual or
1565 alleged act, error, or omission that occurred within the scope
1566 of commission employment, duties, or responsibilities, or that
1567 such person had a reasonable basis for believing occurred within
1568 the scope of commission employment, duties, or responsibilities,
1569 provided that the actual or alleged act, error, or omission did
1570 not result from the intentional, willful, or wanton misconduct
1571 of that person.

1572
1573 ARTICLE VIII

1574 DATA SYSTEM
1575

1576 (1) The commission shall provide for the development,
1577 maintenance, and use of a coordinated database and reporting
1578 system containing licensure, adverse action, and investigative
1579 information on all licensees in member states.

1580 (2) Notwithstanding any other provision of state law to
1581 the contrary, a member state shall submit a uniform data set to
1582 the data system on all individuals to whom the compact is
1583 applicable as required by the rules of the commission, which
1584 data set must include all of the following:

1585 (a) Identifying information.

1586 (b) Licensure data.

1587 (c) Investigative information.

1588 (d) Adverse actions against a license or compact
1589 privilege.

1590 (e) Nonconfidential information related to alternative
1591 program participation.

1592 (f) Any denial of application for licensure, and the
1593 reason for such denial.

1594 (g) Other information that may facilitate the
1595 administration of the compact, as determined by the rules of the
1596 commission.

1597 (3) Investigative information in the system pertaining to
1598 a licensee in any member state must be available only to other
1599 party ~~member~~ states.

1600 (4) The commission shall promptly notify all member states

1601 of any adverse action taken against a licensee or an individual
1602 applying for a license in a member state. Adverse action
1603 information pertaining to a licensee in any member state must be
1604 available to all other member states.

1605 (5) Member states contributing information to the data
1606 system may designate information that may not be shared with the
1607 public without the express permission of the contributing state.

1608 (6) Any information submitted to the data system which is
1609 subsequently required to be expunged by the laws of the member
1610 state contributing the information must be removed from the data
1611 system.

1612
1613 ARTICLE IX

1614 RULEMAKING

1615
1616 (1) The commission shall exercise its rulemaking powers
1617 pursuant to the criteria set forth in this article and the rules
1618 adopted thereunder. Rules and amendments become binding as of
1619 the date specified in each rule or amendment.

1620 (2) If a majority of the legislatures of the member states
1621 rejects a rule by enactment of a statute or resolution in the
1622 same manner used to adopt the compact within 4 years after the
1623 date of adoption of the rule, such rule does not have further
1624 force and effect in any member state.

1625 (3) Rules or amendments to the rules must be adopted at a

regular or special meeting of the commission.

(4) Before adoption of a final rule by the commission, and at least 30 days before the meeting at which the rule will be considered and voted upon, the commission must file a notice of proposed rulemaking on all of the following:

(a) The website of the commission or another publicly accessible platform.

(b) The website of each member state physical therapy licensing board or another publicly accessible platform or the publication in which each state would otherwise publish proposed rules.

(5) The notice of proposed rulemaking must include all of the following:

(a) The proposed date, time, and location of the meeting in which the rule or amendment will be considered and voted upon.

(b) The text of the proposed rule or amendment and the reason for the proposed rule.

(c) A request for comments on the proposed rule or amendment from any interested person.

(d) The manner in which interested persons may submit notice to the commission of their intention to attend the public hearing and any written comments.

(6) Before adoption of a proposed rule or amendment, the commission must allow persons to submit written data, facts,

1651 opinions, and arguments, which must be made available to the
1652 public.

1653 (7) The commission must grant an opportunity for a public
1654 hearing before it adopts a rule or an amendment if a hearing is
1655 requested by any of the following:

1656 (a) At least 25 persons.

1657 (b) A state or federal governmental subdivision or agency.

1658 (c) An association having at least 25 members.

1659 (8) If a scheduled public hearing is held on the proposed
1660 rule or amendment, the commission must publish the date, time,
1661 and location of the hearing. If the hearing is held through
1662 electronic means, the commission must publish the mechanism for
1663 access to the electronic hearing.

1664 (a) All persons wishing to be heard at the hearing must
1665 notify the executive director of the commission or another
1666 designated member in writing of their desire to appear and
1667 testify at the hearing at least 5 business days before the
1668 scheduled date of the hearing.

1669 (b) Hearings must be conducted in a manner providing each
1670 person who wishes to comment a fair and reasonable opportunity
1671 to comment orally or in writing.

1672 (c) All hearings must be recorded. A copy of the recording
1673 must be made available on request.

1674 (d) This article may not be construed to require a
1675 separate hearing on each rule. Rules may be grouped for the

1676 convenience of the commission at hearings required by this
1677 article.

1678 (9) Following the scheduled hearing date, or by the close
1679 of business on the scheduled hearing date if the hearing was not
1680 held, the commission shall consider all written and oral
1681 comments received.

1682 (10) If no written notice of intent to attend the public
1683 hearing by interested parties is received, the commission may
1684 proceed with adoption of the proposed rule without a public
1685 hearing.

1686 (11) The commission shall, by majority vote of all
1687 members, take final action on the proposed rule and shall
1688 determine the effective date of the rule, if any, based on the
1689 rulemaking record and the full text of the rule.

1690 (12) Upon determination that an emergency exists, the
1691 commission may consider and adopt an emergency rule without
1692 prior notice, opportunity for comment, or hearing, provided that
1693 the usual rulemaking procedures provided in the compact and in
1694 this article are retroactively applied to the rule as soon as
1695 reasonably possible, in no event later than 90 days after the
1696 effective date of the rule. For the purposes of this subsection,
1697 an emergency rule is one that must be adopted immediately in
1698 order to do any of the following:

1699 (a) Meet an imminent threat to public health, safety, or
1700 welfare.

(b) Prevent a loss of commission or member state funds.

(c) Meet a deadline for the adoption of an administrative rule established by federal law or rule.

(d) Protect public health and safety.

(13) The commission or an authorized committee of the commission may direct revisions to a previously adopted rule or amendment for purposes of correcting typographical errors, errors in format, errors in consistency, or grammatical errors. Public notice of any revisions must be posted on the website of the commission. The revision is subject to challenge by any person for a period of 30 days after posting. The revision may be challenged only on grounds that the revision results in a material change to a rule. A challenge must be made in writing and delivered to the chair of the commission before the end of the notice period. If a challenge is not made, the revision takes effect without further action. If the revision is challenged, the revision may not take effect without the approval of the commission.

ARTICLE X

OVERSIGHT, DISPUTE RESOLUTION, AND ENFORCEMENT

(1) OVERSIGHT.—

(a) The executive, legislative, and judicial branches of

1726 state government in each member state shall enforce the compact
1727 and take all actions necessary and appropriate to carry out the
1728 compact's purposes and intent. The provisions of the compact and
1729 the rules adopted pursuant thereto shall have standing as
1730 statutory law.

1731 (b) All courts shall take judicial notice of the compact
1732 and the rules in any judicial or administrative proceeding in a
1733 member state pertaining to the subject matter of the compact
1734 which may affect the powers, responsibilities, or actions of the
1735 commission.

1736 (c) The commission is entitled to receive service of
1737 process in any such proceeding and has standing to intervene in
1738 such a proceeding for all purposes. Failure to provide service
1739 of process to the commission renders a judgment or an order void
1740 as to the commission, the compact, or the adopted rules.

1741 (2) DEFAULT, TECHNICAL ASSISTANCE, AND TERMINATION.—

1742 (a) If the commission determines that a member state has
1743 defaulted in the performance of its obligations or
1744 responsibilities under the compact or the adopted rules, the
1745 commission must do all of the following:

1746 1. Provide written notice to the defaulting state and
1747 other member states of the nature of the default, the proposed
1748 means of curing the default, and any other action to be taken by
1749 the commission.

1750 2. Provide remedial training and specific technical

1751 assistance regarding the default.

1752 (b) If a state in default fails to cure the default, the
1753 defaulting state may be terminated from the compact upon an
1754 affirmative vote of a majority of the member states, and all
1755 rights, privileges, and benefits conferred by the compact may be
1756 terminated on the effective date of termination. A cure of the
1757 default does not relieve the offending state of obligations or
1758 liabilities incurred during the period of default.

1759 (c) Termination of membership in the compact may be
1760 imposed only after all other means of securing compliance have
1761 been exhausted. The commission shall give notice of intent to
1762 suspend or terminate a defaulting member state to the governor
1763 and majority and minority leaders of the defaulting state's
1764 legislature and to each of the member states.

1765 (d) A state that has been terminated from the compact is
1766 responsible for all assessments, obligations, and liabilities
1767 incurred through the effective date of termination, including
1768 obligations that extend beyond the effective date of
1769 termination.

1770 (e) The commission does not bear any costs related to a
1771 state that is found to be in default or that has been terminated
1772 from the compact, unless agreed upon in writing between the
1773 commission and the defaulting state.

1774 (f) The defaulting state may appeal the action of the
1775 commission by petitioning the United States District Court for

the District of Columbia or the federal district where the commission has its principal offices. The prevailing member shall be awarded all costs of such litigation, including reasonable attorney fees.

(3) DISPUTE RESOLUTION.—

(a) Upon request by a member state, the commission must attempt to resolve disputes related to the compact which arise among member states and between member and nonmember states.

(b) The commission shall adopt a rule providing for both mediation and binding dispute resolution for disputes as appropriate.

(4) ENFORCEMENT.—

(a) The commission, in the reasonable exercise of its discretion, shall enforce the compact and the commission's rules.

(b) By majority vote, the commission may initiate legal action in the United States District Court for the District of Columbia or the federal district where the commission has its principal offices against a member state in default to enforce compliance with the provisions of the compact and its adopted rules and bylaws. The relief sought may include both injunctive relief and damages. In the event judicial enforcement is necessary, the prevailing member shall be awarded all costs of such litigation, including reasonable attorney fees.

(c) The remedies under this article are not the exclusive

remedies of the commission. The commission may pursue any other remedies available under federal or state law.

ARTICLE XI
DATE OF IMPLEMENTATION OF THE
PHYSICAL THERAPY COMPACT
AND ASSOCIATED RULES;
WITHDRAWAL; AND AMENDMENTS

(1) The compact becomes effective on the date that the compact statute is enacted into law in the tenth member state. The provisions that become effective at that time are limited to the powers granted to the commission relating to assembly and the adoption of rules. Thereafter, the commission shall meet and exercise rulemaking powers necessary for the implementation and administration of the compact.

(2) Any state that joins the compact subsequent to the commission's initial adoption of the rules is subject to the rules as they exist on the date that the compact becomes law in that state. Any rule that has been previously adopted by the commission has the full force and effect of law on the day the compact becomes law in that state.

(3) Any member state may withdraw from the compact by enacting a statute repealing the same.

(a) A member state's withdrawal does not take effect until

1826 6 months after enactment of the repealing statute.

1827 (b) Withdrawal does not affect the continuing requirement
1828 of the withdrawing state's physical therapy licensing board to
1829 comply with the investigative and adverse action reporting
1830 requirements of this act before the effective date of
1831 withdrawal.

1832 (4) The compact may not be construed to invalidate or
1833 prevent any physical therapy licensure agreement or other
1834 cooperative arrangement between a member state and a nonmember
1835 state which does not conflict with the provisions of the
1836 compact.

1837 (5) The compact may be amended by the member states. An
1838 amendment to the compact does not become effective and binding
1839 upon any member state until it is enacted into the laws of all
1840 member states.

1841
1842 ARTICLE XII

1843 CONSTRUCTION AND SEVERABILITY
1844

1845 The compact must be liberally construed so as to carry out
1846 the purposes thereof. The provisions of the compact are
1847 severable, and if any phrase, clause, sentence, or provision of
1848 the compact is declared to be contrary to the constitution of
1849 any party ~~member~~ state or of the United States or the
1850 applicability thereof to any government, agency, person, or

1851 circumstance is held invalid, the validity of the remainder of
1852 the compact and the applicability thereof to any government,
1853 agency, person, or circumstance is not affected thereby. If the
1854 compact is held contrary to the constitution of any party member
1855 state, the compact remains in full force and effect as to the
1856 remaining party member states and in full force and effect as to
1857 the party member state affected as to all severable matters.

1858 Section 17. Except as otherwise expressly provided in this
1859 act and except for this section, which shall take effect upon
1860 this act becoming a law, or, if this act fails to become a law
1861 until after June 1, 2025, it shall take effect upon becoming a
1862 law and shall operate retroactively to June 1, 2025, this act
1863 shall take effect July 1, 2025.
1864